Welcome to our dedicated page for Revolution Medicines news (Ticker: RVMD), a resource for investors and traders seeking the latest updates and insights on Revolution Medicines stock.
Revolution Medicines, Inc. (RVMD) is a clinical-stage precision oncology company dedicated to discovering and developing innovative targeted therapies that address the unmet needs of cancer patients. The company leverages its proprietary product engine to target frontier oncology pathways, with a strong focus on the RAS and mTOR signaling pathways, which are crucial for cancer growth and survival. Revolution Medicines’ approach draws inspiration from nature and evolution, harnessing insights from natural products to guide the discovery and development of small molecules that modulate key cancer targets.
The company’s research and development pipeline features several promising candidates, including RMC-4630, a SHP2 inhibitor, and a portfolio of RAS(ON) inhibitors such as RMC-6236, RMC-6291, and RMC-9805. These novel therapies aim to inhibit the active form of RAS proteins, which are common drivers in numerous cancer types. Revolution Medicines is also advancing the SOS1 and 4EBP1/mTORC1 programs, which hold significant potential in combination treatment strategies.
Recent achievements highlight the company’s progress in clinical development. Notably, the RMC-6236 Phase 1/1b trial demonstrated promising clinical activity and a favorable safety profile in patients with advanced solid tumors harboring KRAS mutations. The trial results showed an objective response rate of 38% in non-small cell lung cancer (NSCLC) and 20% in pancreatic ductal adenocarcinoma (PDAC), with disease control rates of 85% and 87%, respectively.
In October 2023, Revolution Medicines announced a pivotal milestone with the merger with EQRx, Inc., enhancing its financial position and enabling further investment in its clinical programs. The merger is expected to add approximately $1.1 billion in net cash proceeds, supporting the advancement of their RAS(ON) and RAS Companion Inhibitors. Dr. Sandra Horning, a renowned oncologist and former Genentech executive, joined the board of directors, bringing invaluable experience to the company.
Revolution Medicines continues to engage the scientific community and stakeholders through presentations at major conferences and investor webcasts. The company remains committed to advancing its robust pipeline of oncology therapies, aiming to revolutionize the treatment landscape for RAS-addicted cancers and improve outcomes for cancer patients worldwide.
Revolution Medicines announced the initiation of a multicenter Phase 1/1b clinical trial for RMC-5552, a first-in-class bi-steric mTORC1 inhibitor targeting relapsed/refractory solid tumors. The trial aims to assess the drug's safety, tolerability, and preliminary efficacy. Additionally, the U.S. Patent Office issued Patent No. 10,980,889, providing composition protection for RMC-5552 and related compounds. This advancement aligns with the company's focus on developing therapies for RAS-addicted cancers, crucial given the biological complexities of these tumors.
Revolution Medicines (Nasdaq: RVMD) announced six presentations at the AACR Annual Meeting 2021, scheduled for April 10-15, showcasing advancements in their RAS(ON) Inhibitors and RAS Companion Inhibitors. Notable presentations include the SHP2 inhibitor RMC-4630's anti-tumor activity and the development of first-in-class KRAS G12V inhibitors. The event emphasizes the company's commitment to precision oncology and highlights their ongoing research in treating RAS-addicted cancers.
Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage precision oncology company, announced participation in two investor conferences. CEO Mark A. Goldsmith will present at the Oppenheimer 31st Annual Healthcare Conference on March 16, 2021, from 1:10 to 1:40 p.m. Eastern. Additionally, he will participate in a fireside chat at the J.P. Morgan 10th Annual Napa Valley Forum on March 29, 2021, from 2:00 to 2:45 p.m. Eastern. Revolution Medicines focuses on developing targeted therapies for RAS-addicted cancers, with R&D initiatives around RAS(ON) and Companion Inhibitors.
Revolution Medicines (Nasdaq: RVMD) announced significant advancements in its RAS(ON) inhibitor development, entering IND-enabling stages for two candidates, RMC-6291 and RMC-6236. Both are aimed at addressing RAS-addicted cancers. The company successfully raised $281 million in net proceeds to fund these efforts. However, financial results revealed a decline in revenue, with full-year totals down from $50 million in 2019 to $43 million in 2020. The net loss also increased to $108.2 million in 2020, up from $47.7 million the previous year, with guidance suggesting a further loss of $170 million to $190 million for 2021.
Revolution Medicines (Nasdaq: RVMD) announced participation in the Digital RAS-Targeted Drug Discovery Summit from February 23-25, 2021. Steve Kelsey, M.D., will present on RAS(ON) Inhibitor programs, including RMC-6291 and RMC-6236, which are in IND-enabling development. Kelsey will also join a panel discussion on mechanisms of resistance in combination therapies. Additionally, Revolution Medicines will participate in three upcoming investor conferences, with presentations scheduled for February and March 2021.
Revolution Medicines (Nasdaq:RVMD) announced the closing of a public offering of 6,666,666 shares at $45.00 each, totaling gross proceeds of $300 million. This includes 869,565 additional shares sold after underwriters exercised their option. The offering was managed by J.P. Morgan, Cowen, SVB Leerink, and Guggenheim Securities, with prior SEC registration on February 3, 2021. Funds will support the company’s focus on developing targeted therapies for RAS-addicted cancers.
Revolution Medicines (Nasdaq: RVMD) has priced its underwritten public offering of 5,797,101 shares of common stock at $45.00 per share, aiming to raise approximately $260.9 million in gross proceeds. The offering includes a 30-day option for underwriters to purchase an additional 869,565 shares. The closing of this offering is anticipated on February 8, 2021, pending customary conditions. This fundraising initiative is aimed at advancing the company's pipeline focused on targeted therapies for RAS-addicted cancers.
Revolution Medicines (Nasdaq: RVMD) has initiated an underwritten public offering of 4,000,000 shares of common stock, with an option for underwriters to purchase an additional 600,000 shares.
Major banks including J.P. Morgan, Cowen, SVB Leerink, and Guggenheim Securities are serving as joint book-running managers for this offering. The offering is made through a registered prospectus filed with the SEC. This press release does not qualify as an offer to sell or buy these securities in jurisdictions where it is unlawful prior to registration.
Revolution Medicines (Nasdaq: RVMD) announced that CEO Mark A. Goldsmith will present at the 39th Annual J.P. Morgan Healthcare Conference from January 11-14, 2021. During the presentation, scheduled for January 12 at 5:20 p.m. Eastern, Dr. Goldsmith will discuss the advancement of two first-in-class RAS(ON) Inhibitor programs into IND-enabling development. He will also provide updates on three RAS Companion Inhibitors: RMC-4630, RMC-5552, and the newly introduced RMC-5845. The presentation will be available via webcast on the company's website.
Revolution Medicines (RVMD) provided an update on its RMC-4630 programs for RAS-addicted cancers, announcing selected Phase 2 doses for both monotherapy and combination therapies. Financial results for Q3 2020 show revenue of $12.7 million, up from $12.5 million in Q3 2019. However, R&D expenses rose to $34.9 million, leading to a net loss of $27.2 million, compared to a loss of $12.8 million in the previous year. The company has positioned itself as a leader in RAS-targeted therapies and has extended its clinical collaborations to enhance its drug development pipeline.
FAQ
What is the current stock price of Revolution Medicines (RVMD)?
What is the market cap of Revolution Medicines (RVMD)?
What does Revolution Medicines, Inc. specialize in?
What are some of the key products in Revolution Medicines’ pipeline?
What recent achievements has Revolution Medicines reported?
What is the significance of the RMC-6236 Phase 1/1b trial?
How does the merger with EQRx benefit Revolution Medicines?
Who recently joined the board of Revolution Medicines?
What are RAS(ON) inhibitors?
How does Revolution Medicines generate insights for its drug discovery?
What are some of the ongoing trials at Revolution Medicines?
How can investors stay updated on Revolution Medicines’ developments?
